相关临床试验
32
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
27
84.4%
终止
5
15.6%
暂无批准数据
- VYNE Therapeutics distributed a special cash dividend of approximately $16.5 million to stockholders on July 23, 2026, fulfilling a key condition of its pending merger with Yarrow Bioscience. - A 1-for-50 reverse stock split is expected on July 24, 2026, with the combined company to begin trading on Nasdaq under the ticker "YARW" following merger close. - The merger brings together VYNE's InhiBET platform and Yarrow's YB-101, a potentially first-in-class anti-TSHR monoclonal antibody targeting Graves' disease and thyroid eye disease. - Closing of the merger is anticipated early in the week of July 27, 2026, subject to final Nasdaq listing approval.
- GenSci and RTW Investments announced a strategic partnership granting Yarrow Bioscience exclusive global ex-China rights to develop GS-098 (YB-101), a first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease. - The deal includes a $70 million upfront payment and potential milestone payments totaling up to $1.365 billion, with GenSci retaining development and commercialization rights in China. - YB-101 represents a novel targeted approach that selectively blocks thyroid-stimulating autoantibodies without systemic immunosuppression, addressing significant unmet medical needs in autoimmune thyroid disorders. - Yarrow plans to advance YB-101 into a U.S.-based Phase 1b/2b trial for Graves' disease in the first half of 2026, with Phase 1b data expected in the second half of 2027.
- Over 18 companies are actively developing 20+ pipeline therapies for vitiligo treatment, with JAK inhibitors leading the charge in late-stage clinical trials. - AbbVie's Upadacitinib and Pfizer's Ritlecitinib have both advanced to Phase 3 trials, demonstrating promising repigmentation results in vitiligo patients. - Novel approaches include Clinuvel's Afamelanotide in Phase 3 trials and Amgen's AMG 714 anti-IL-15 monoclonal antibody in Phase 2 development. - The pipeline reflects a paradigm shift towards targeted therapies and personalized medicine approaches, offering new hope for patients with this challenging autoimmune condition.
- VYNE Therapeutics announced that its phase 2b trial of repibresib gel in nonsegmental vitiligo failed to meet primary and key secondary endpoints, with only 19.5% of patients achieving F-VASI50 improvement compared to 23.4% on vehicle. - The trial was impacted by an unexpectedly high vehicle effect and higher dropout rates in active treatment arms (up to 36.6%) compared to vehicle (10.6%). - Despite the setbacks, the highest dose (3%) showed nominally significant improvements in facial vitiligo scores (-43.6% vs -25.6% vehicle) and total vitiligo scores (-28.3% vs -16.2% vehicle). - The company will terminate the trial's extension phase and seek a development partner for repibresib while continuing to evaluate its BET inhibitor platform for immune-mediated diseases.
- MindMed has appointed Matt Wiley as Chief Commercial Officer to oversee the commercial strategy for MM120 ODT, a potential treatment for generalized anxiety disorder and major depressive disorder. - Wiley brings over 25 years of experience in specialty product launches, including successful commercialization of neuroscience therapeutics like XYREM®, which achieved blockbuster status under his leadership. - The appointment comes as MindMed prepares for multiple Phase 3 clinical readouts in 2026, positioning the company to potentially address the needs of over 50 million people suffering from anxiety and depression.
- VYNE Therapeutics completes enrollment for Phase 2b trial of VYN201 gel (repibresib) in nonsegmental vitiligo, with top-line data expected mid-2025. - A Phase 1b trial of oral VYN202 for moderate-to-severe plaque psoriasis has begun, with results anticipated by the end of 2025. - Both VYN201 and VYN202 are BET inhibitors designed to address immune-mediated conditions with high unmet needs.
- A Phase 1b trial of VYN201 topical gel demonstrated safety and tolerability in patients with active non-segmental vitiligo (aNSV). - The study showed a dose-dependent clinical response, with the 2% dose cohort experiencing a -39.0% change in F-VASI score after 16 weeks. - VYN201, a topical small molecule BET inhibitor, aims to minimize disease severity and encourage anti-inflammatory effects in vitiligo patients. - The findings suggest VYN201 could address the significant unmet need for new therapies in vitiligo, offering a novel approach beyond existing treatments.
